Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents

Vaccine

Volumn 28, Issue 37, 2010, Pages 5993-5997

  Beran, Jiri ^a   Kervyn, Diane ^b   Wertzova, Veronika ^a   Hobzova, Lenka ^a   Tichy, Petr ^c   Kuriyakose, Sherine ^d   Leyssen, Maarten ^e   Jacquet, Jeanne Marie ^e  

^a Vaccination and Travel Medicine Centre   (Czech Republic)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GlaxoSmithKline Pharmaceuticals Ltd   (India)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Combined; Hepatitis; Two dose

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; VACCINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FORMULATION; FEMALE; FOLLOW UP; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION; BLOOD; COMPARATIVE STUDY; IMMUNIZATION; IMMUNOLOGY;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; VACCINES, COMBINED;

EID: 77955509544     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.104     Document Type: Article

References (18)

1. World Health Organisation, Dept. of Communicable diseases surveillance and Response. WHO/CDC/CSR/LYO/2002.2: Hepatitis B. Available: [accessed on 14.4.09]. http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf.
2. World Health Organisation (WHO) Hepatitis A position paper. Wkly Epidemiol Rec 2000, 75:38-42.
3. Hadler S.C. Global impact of hepatitis A virus infection; changing patterns. Viral hepatitis and liver disease 1991, 14-20. Williams and Wilkins, Baltimore. F.B. Hollinger, S.M. Lemon, H. Margolis (Eds.).
4. World Health Organisation (WHO). Hepatitis B Fact sheet. Available: [accessed on 18.8.09]. http://www.who.int/mediacentre/factsheets/fs204/en/.
5. Van Der Wielen M., Van Damme P., Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J 2000, 19:848-853.
6. Van Herck K., Van Damme P., Collard F., Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. Scand J Gastroenterol 1999, 34:1236-1240.
7. Van Herck K., Leroux-Roels G., Van Damme P., Srinivasa K., Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix™) in adults. Travel Med Infect Dis 2007, 5:171-175.
8. Van Damme P., Leroux-Roels G., Law B., Diaz-Mitoma F., Desombere I., Collard F., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001, 65:6-13.
9. Burgess M., Rodger A. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine Twinrix™ in healthy adolescent volunteers an open randomised study. Vaccine 2001, 19:4835-4841.
10. World Health Organisation (WHO) Hepatitis B position paper. Wkly Epidemiol Rec 2004, 79:253-264.
11. World Health Organisation (WHO). Hepatitis A fact sheet. Available: [accessed on 04.5.2010]. http://www.who.int/mediacentre/factsheets/fs328/en/index.html.
12. Beran J. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine. Expert Rev Vaccines 2007, 6:891-902.
13. Levie K., Beran J., Collard F., Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine 2002, 20:2579-2584.
14. Thoelen S., Van Damme P., Leentvaar-Kuypers A., Leroux-Roels G., Bruguera M., Frei P.C., et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999, 17:1657-1662.
15. Banatvala J., Kane M., Da Villa G., Esteban R., Franco E., Goudeau A., et al. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
16. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
17. Gabbuti A., Romano L., Blanc P., Meacci F., Amendolab A., Melec A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007, 25:3129-3132.
18. Kurugol Z., Mutlubas F., Ozacar T. A two-dose schedule of a combined hepatitis A and B vaccination in children aged 6-15 years. Vaccine 2005, 23:2876-2880.